Euglycemic DKA on SGLT2 Inhibitors: How to Recognize and Treat It in Emergencies

Most people think diabetic ketoacidosis (DKA) means high blood sugar. If your glucose is under 250 mg/dL, you’re probably safe - right? Wrong. A growing number of diabetic patients on SGLT2 inhibitors are developing a dangerous form of DKA called euglycemic DKA, where blood sugar stays normal or only slightly elevated, but ketones build up to life-threatening levels. This isn’t rare. It’s underdiagnosed, often missed, and sometimes fatal because doctors and patients alike assume normal glucose means no problem.

What Is Euglycemic DKA?

Euglycemic diabetic ketoacidosis (EDKA) is a metabolic emergency that looks like classic DKA - acidosis, ketones in the blood, nausea, vomiting, trouble breathing - but with blood glucose below 250 mg/dL. That’s the key difference. Traditional DKA usually hits with glucose over 300 or even 400 mg/dL. EDKA slips under the radar because it doesn’t scream "diabetes crisis." It whispers.

This condition became widely recognized after 2015, when the FDA issued a safety alert after multiple cases were reported in patients taking SGLT2 inhibitors like dapagliflozin (Farxiga), empagliflozin (Jardiance), and canagliflozin (Invokana). These drugs work by making the kidneys flush out extra sugar. Sounds good - until it backfires.

Here’s how it breaks down: SGLT2 inhibitors lower blood sugar by pushing glucose out in urine. That sounds helpful. But it also tricks the body into thinking it’s low on fuel. The pancreas responds by releasing more glucagon (a hormone that raises blood sugar) and suppressing insulin just enough to stop glucose from being used. Result? Fat breaks down rapidly into ketones. No sugar spike. No warning sign. Just rising ketones and a ticking clock.

Who’s at Risk?

EDKA doesn’t care if you have type 1 or type 2 diabetes. But certain situations make it much more likely:

• Illness - flu, infection, pneumonia
• Reduced food intake - fasting, dieting, not eating for 24+ hours
• Surgery or trauma
• Pregnancy
• Alcohol use
• Stopping insulin or reducing doses

Shockingly, about 20% of EDKA cases happen in people with type 2 diabetes who’ve never had DKA before. That’s why it’s so dangerous - no history, no awareness.

Even worse, SGLT2 inhibitors are sometimes used off-label in type 1 diabetes - even though they’re not FDA-approved for that. Around 8% of type 1 patients are on them, and in this group, DKA rates jump to 5-12%. Many of those cases are euglycemic.

Symptoms - They’re Subtle, But Deadly

EDKA doesn’t come with a flashing red light. The symptoms are vague, easy to dismiss:

• Nausea and vomiting (85% of cases)
• Abdominal pain (65%) - often mistaken for food poisoning or gallbladder issues
• Unusual tiredness or weakness (76%)
• Deep, rapid breathing (Kussmaul respirations) (62%)
• General malaise (91%)

Unlike classic DKA, the fruity-smelling breath isn’t always there. That’s because ketone levels are lower, not because the problem is less serious. In fact, the absence of this classic sign can make providers think, "This isn’t DKA." And that’s when mistakes happen.

A 2015 study in Diabetes Care tracked 13 cases across U.S. hospitals. In every single case, the patient’s glucose was below 250 mg/dL. In half of them, it was under 200 mg/dL. Each delay in diagnosis cost time - and sometimes lives.

How to Diagnose It

There’s no single test. You need three things:

1. Blood glucose under 250 mg/dL
2. Metabolic acidosis (pH < 7.3, bicarbonate < 18 mEq/L)
3. Elevated ketones - either in blood (beta-hydroxybutyrate > 3 mmol/L) or urine

Don’t rely on urine dipsticks alone. They detect acetoacetate, not beta-hydroxybutyrate - the main ketone in EDKA. Blood ketone meters are far more accurate. In emergency settings, the Cleveland Clinic now requires serum beta-hydroxybutyrate testing within 15 minutes for any diabetic on an SGLT2 inhibitor with nausea or vomiting.

Also, don’t assume high white blood cell count means infection. About 40% of EDKA patients have leukocytosis, but it’s often from dehydration, not sepsis.

Emergency Treatment - It’s Not Just Insulin and Fluids

Treating EDKA is similar to classic DKA - but with critical twists.

Step 1: Fluids - Start with 0.9% saline at 15-20 mL/kg over the first hour. Dehydration is common. But don’t overdo it. You’re not trying to lower glucose - you’re trying to restore volume and kidney function.

Step 2: Insulin - Give 0.1 units/kg/hour IV. But here’s the catch: because glucose is already low, you can’t wait to see it drop before adding sugar. In classic DKA, you hold insulin until glucose hits 250. In EDKA, you start glucose-containing fluids (like 5% dextrose) when glucose falls below 150-200 mg/dL. Otherwise, you risk severe hypoglycemia.

Step 3: Potassium - Even if serum potassium looks normal, total body potassium is usually low. About 65% of EDKA patients need potassium replacement. Check levels hourly. Don’t wait for it to drop.

Step 4: Monitor ketones - Track beta-hydroxybutyrate every 2-4 hours. Acidosis resolves as ketones fall. Don’t stop treatment just because glucose normalizes.

Many EDKA patients end up in the ICU. The key is early recognition. Waiting for glucose to rise is a deadly gamble.

Why This Keeps Happening

SGLT2 inhibitors are prescribed heavily - about 25% of new diabetes scripts in the U.S. are for these drugs. Dapagliflozin and empagliflozin alone account for 80% of that market. They’re popular because they help with weight loss, blood pressure, and heart protection.

But the risk is real. Studies show patients on SGLT2 inhibitors have a 7-fold higher risk of DKA than those on other diabetes drugs. And while overall DKA cases have dropped 32% since 2015 due to awareness, EDKA now makes up 41% of all SGLT2-related DKA cases - up from 28%. That means we’re getting better at spotting it… but it’s still slipping through.

Why? Cognitive bias. Doctors are trained to link DKA with high sugar. When glucose is normal, the brain says, "Not DKA." That’s the trap.

How to Prevent It

Prevention is simple - if you know what to do:

• Stop SGLT2 inhibitors during illness, surgery, or fasting - even if you feel fine.
• Check ketones if you’re nauseous, vomiting, or exhausted - no matter what your glucose reading is.
• Don’t skip meals. Even if you’re trying to lose weight, your body needs fuel during stress.
• If you have type 1 diabetes, avoid SGLT2 inhibitors unless closely supervised by an endocrinologist.
• Patients should carry a card or app alert that says: "I take an SGLT2 inhibitor. If I feel sick, test my ketones."

The FDA now requires all SGLT2 inhibitor packaging to include this warning: "Stop taking this medication and seek immediate medical attention if you have symptoms of ketoacidosis, even if your blood sugar is normal."

What’s Next?

Researchers are looking for early warning signs. A 2023 study found that a high ratio of acetoacetate to beta-hydroxybutyrate in the blood, measured 24 hours before symptoms appear, predicts EDKA with 87% accuracy. That could lead to home monitoring tools.

Meanwhile, a national study (NCT04987231) is testing whether combining HbA1c variability with C-peptide levels can identify high-risk patients. Early results show 82% accuracy.

One thing’s clear: SGLT2 inhibitors aren’t going away. They’re too useful. But we need to change how we think about DKA. It’s not about sugar. It’s about ketones. And if you’re on one of these drugs, your body can go into ketoacidosis - even when your glucose looks perfect.